HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYN

Hematology

Allogeneic CAR T Cleared for B-cell Malignancy Trials

Sana Biotechnology also plans to submit another IND for the same indications for a CD22-targeted CAR T later in 2022.

Cilta-cel CARTITUDE-4 Trial to be Unblinded After Meeting Primary End Point

Cilta-cel demonstrated a significant improvement in progression-free survival over standards of care.

CGTLive’s Weekly Rewind – January 27, 2023

Review top news and interview highlights from the week ending January 27, 2023.